Related Experiment Videos
Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer. A Southwest Oncology
D D Von Hoff1, S Green, E A Surwit
1University of Texas Health Science Center, San Antonio 78284-7884.
American Journal of Clinical Oncology
|October 1, 1990
Abstract:
Twenty evaluable patients with advanced cervical cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicities were anemia and leukopenia. Based on this study, fludarabine phosphate does not appear to be an active agent for patients with chemotherapy refractory cervical cancer.